Related Experiment Videos
COX-2 - a target for preventing hepatic carcinoma?
Mohammad A Rahman1, Hitoshi Kohno, Naofumi Nagasue
1Second Department of Surgery, Shimane Medical University, Izumo 693-8501, Japan. rahman@shimane-med.ac.jp
Expert Opinion on Therapeutic Targets
|September 12, 2002
Summary
Hepatocellular carcinoma (HCC) is a deadly cancer, prompting research into prevention. Overexpression of cyclooxygenase-2 (COX-2) may drive liver cancer development, suggesting COX-2 inhibitors as a potential preventive strategy.
Area of Science:
- Oncology
- Molecular Biology
- Carcinogenesis
Background:
- Hepatocellular carcinoma (HCC) presents a significant global health challenge, particularly in Africa, Asia, and Taiwan.
- Despite advances in diagnosis and treatment, HCC prognosis remains poor, highlighting the need for effective prevention strategies.
- Overexpression of inducible cyclooxygenase-2 (COX-2), an immediate-early response gene, is implicated in various cancers, including HCC.
Purpose of the Study:
- To investigate the role of cyclooxygenase-2 (COX-2) in hepatic carcinogenesis.
- To explore the potential of targeting COX-2 for the prevention of hepatocellular carcinoma (HCC).
Main Methods:
- Review of existing literature on COX-2 expression and function in carcinogenesis.
- Analysis of COX-2's molecular mechanisms, including angiogenesis and apoptosis regulation.
Main Results:
- COX-2 overexpression is suggested to be a key factor in liver cancer development.
- COX-2 promotes angiogenesis via vascular endothelial growth factor (VEGF) and prostaglandins.
- COX-2 inhibits apoptosis by upregulating Bcl-2 and activating Akt/PKB signaling.
Conclusions:
- Targeting COX-2 activity through selective inhibitors may represent a promising strategy for preventing hepatocellular carcinoma (HCC).
- Further research into COX-2 inhibition could lead to novel approaches for HCC chemoprevention.